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| INTRODUCTION
According to the updated Sapporo criteria, the diagnosis of antiphospholipid syndrome (APS) implies vascular thrombosis and/or pregnancy morbidity and at least 1 of the 3 antiphospholipid antibodies (aPLs) (ie, lupus anticoagulant [LAC] , anticardiolipin [aCL] immunoglobulin (Ig) G/IgM antibodies and anti-β2 glycoprotein I
[aβ2GPI] IgG/IgM antibodies). 1 The "classical" clinical characteristics of APS include vascular thrombosis and pregnancy morbidity.
However, APS may be associated with a wide variety of other clinical symptoms, including thrombocytopenia, heart valve disease, livedo reticularis, nephropathy, and neurological manifestations, which are considered noncriteria manifestations of APS. analytical performance. 3, 4 For all assays, the cutoff value should be carefully chosen because the sensitivity and specificity of diagnostic laboratory testing for aPL strongly depend on the cutoff value. 5 In analogy with LAC, the Scientific and Standardization Committee on Lupus Anticoagulant/Antiphospholipid Antibodies (SSC-aPL) of the International Society of Thrombosis and Haemostasis (ISTH) recommends the use of the 99th percentile of a reference population as the cutoff to maximize specificity. 6, 7 Therefore, a minimum of 120 reference subjects should be used, taking into consideration the age and type of population most representative for each laboratory. 6 Unfortunately, these in-house calculated cutoff values may be significantly different from those recommended by the manufacturers. [8] [9] [10] In fact, the value may depend on the performance characteristics, the statistical method and the reference population used to establish cutoff values. Reaching a consensus on the method for cutoff establishment is important from the viewpoint of harmonization of aPL measurement.
To study cutoff establishment in clinical laboratories, we pre- 
| MATERIALS AND METHODS

| Questionnaire on cutoff values for aPL with solid-phase assays
A questionnaire (see the Supplementary Data) was sent by email to 318 SSC-aPL members and 575 participants of the "Lupus Program"
external quality exercises of the ECAT Foundation. SSC-aPL members are workers in the field of aPL who expressed their interest in the SSC-aPL by signing up on the ISTH website.
| Selection of normal controls
A total of 120 normal controls (71 females and 49 males; mean age, 56 years; range, 44-65 years) were recruited from healthy local volunteers at Ghent University Hospital (Ghent, Belgium). In collaboration with Jagiellonian University Medical College (Krakow, Poland), the normal population was expanded with another 80 healthy volunteers, giving rise to a sample size of 200 (129 females and 71 males; mean age, 53 years; range, 20-71 years). All healthy volunteers were selected for blood sampling after declaring good health by a questionnaire. They were free from overt cardiovascular disease, conventional risk factors, and medication.
| Selection of patient groups
Patients with APS, patients with non-APS disease, and healthy controls were enrolled at Ghent University Hospital and Jagiellonian University Medical College. The patients were selected by the enrollment center out of a population referred for autoimmune disease, hypercoagulability, or prolonged clotting time with a request for aPL measurement. They were assigned to the following categories based on both clinical data and results of local laboratory investigations:
1. Group A consisted of patients with thrombotic APS according to the Sydney revised Sapporo guidelines. 1 Of these patients,
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TA B L E 1 Assay characteristics
2. Group B consisted of patients who had a history of thrombosis and were negative for laboratory criteria of APS ("diseased controls"). Numbers in each center were as follows: Ghent, n = 138; Krakow, n = 0. The study was approved by the ethics committees of both centers included in the study.
| Assays
Citrated plasmas from all patients and controls were retested for aCL and aβ2GPI IgG/IgM antibodies at 1 site (Ghent University Hospital) using 4 commercial assays: 
| Statistical analysis
All results from normal controls were tested to assess deviation were set as outcome variable rather than APS/non-APS in order to be independent of aPL presence previously detected to minimize selection bias. P values associated with odds ratios were calculated by Fisher's exact test. A P < 0.05 was considered to be statistically significant.
All statistical analyses were performed using Analyse-it 4.81. 
| RESULTS
| Questionnaire on cutoff values for aPL with solid-phase assays
We received 139 answers from all over the world, yielding a response The question "Which method do you use to identify outliers?"
showed that 61.5% of the laboratories checked for outliers by different methods as illustrated in Figure 1B , of which 68.4% effectually excluded outliers; 31.6% followed the recommendations to check the calculated cutoff value by a clinical approach in the local patient population by calculating sensitivity and specificity regarding the association with thrombotic/pregnancy complications, 6 and 72.7% adapted their cutoff values accordingly, based on the criterion of sensitivity >95% (37.5%), specificity >95% (37.5%) or choosing the highest odds ratio (25%).
| Calculation of cutoff values on a normal population
The results for aCL and aβ2GPI IgG/IgM antibodies from normal controls showed a nonparametric (positively right skewed) distribution.
Not all data sets could be normalized due to the clustering of identical low values at the bottom of the distribution. Hence, it was decided to calculate cutoff values by means of nonparametric procedures.
The derived cutoff values for aPL are presented in Tables S1 and   S2 . As expected, higher cutoff values were found when calculated as 99th rather than 95th percentiles. Notably, the statistical method had considerable impact on the estimated cutoffs. When all different methods for percentile calculation were combined with all different outlier elimination methods and the 99th (95th) percentiles obtained were compared, >11-(>2-) and >8-(>1-) fold difference was obtained using data from 120 and 200 normal controls, respectively.
The 99th percentiles of 120 normal controls by method A were 31.1 U/mL for aβ2GPI IgM, 209.2 U/mL for aCL IgM, 136.2 U/mL for aβ2GPI IgG, and 42.5 U/mL for aCL IgG using HemosIL AcuStar. For
BioPlex, these values were found to be 65.4 U/mL, 59.8 MPL-U/mL, 123.6 U/mL and 132 GPL-U/mL, respectively; for EliA, 21.3 U/mL, Table 2 .
A graphical presentation of the local derived cutoff values based on 120 normal controls is given in Figure 2 . The value recommended by the manufacturer is indicated for comparison. In general, the 95th percentile cutoffs were lower than the manufacturers' cutoffs. In contrast, the 99th percentile cutoffs were equal to or higher than the manufacturers' cutoffs.
| Agreement of the 4 assays for aPL testing
HemosIL AcuStar, BioPlex, EliA, and QUANTA Lite were compared using 573 samples. Figure 3 shows the kappa statistics among the HemosIL AcuStar, BioPlex, EliA, and QUANTA Lite aPL panels at different cutoffs defining positivity.
With the manufacturers' cutoff (dotted lines in Figure 3 6 Kappa values 99th P method A, no outlier 99th P method A, Reed 99th P method A, TM 99th P method B, no outlier 99th P method B, Reed 99th P method B, TM 95th P method A, Reed 95th P method A, TM 95th P method B, no outlier 95th P method A, no outlier 95th P method B, Reed 95th P method B, TM 99th P method A, no outlier 99th P method A, Reed 99th P method A, TM 99th P method B, no outlier 99th P method B, Reed 99th P method B, TM 95th P method A, Reed 95th P method A, TM 95th P method B, no outlier 95th P method A, no outlier 95th P method B, Reed 95th P method B, TM 99th P method A, no outlier 99th P method A, Reed 99th P method A, TM 99th P method B, no outlier 99th P method B, Reed 99th P method B, TM 95th P method A, Reed 95th P method A, TM 95th P method B, no outlier 95th P method A, no outlier 95th P method B, Reed 95th P method B, TM 99th P method A, no outlier 99th P method A, Reed 99th P method A, TM 99th P method B, no outlier 99th P method B, Reed 99th P method B, TM 95th P method A, Reed 95th P method A, TM 95th P method B, no outlier 95th P method A, no outlier 95th P method B, 95% CI 95% CI YI (%) Spec (%) BioPlex 99th P method A, Reed 99th P method A, TM 99th P method B, no outlier 99th P method B, Reed 99th P method B, TM 95th P method A, Reed 95th P method A, TM 95th P method B, no outlier 95th P method A, no outlier 95th P method B, Reed 95th P method B, TM 99th P method A, no outlier 99th P method A, Reed 99th P method A, TM 99th P method B, no outlier 99th P method B, Reed 99th P method B, TM 95th P method A, Reed 95th P method A, TM 95th P method B, no outlier 95th P method A, no outlier 95th P method B, Reed 95th P method B, TM Manufacturer's cutoff EliA 99th P method A, no outlier 99th P method A, Reed 99th P method A, TM 99th P method B, no outlier 99th P method B, Reed 99th P method B, TM 95th P method A, Reed 95th P method A, TM 95th P method B, no outlier 95th P method A, no outlier 95th P method B, Reed 95th P method B, TM Manufacturer's cutoff QUANTA Lite 99th P method A, no outlier 99th P method A, Reed 99th P method A, TM 99th P method B, no outlier 99th P method B, Reed 99th P method B, TM 95th P method A, Reed 95th P method A, TM 95th P method B, no outlier 95th P method A, no outlier 
| Diagnostic performances
We compared the results for aCL and aβ2GPI antibodies obtained All aCL and aβ2GPI IgM assays showed a poor relationship with thrombotic events. In contrast, IgG positivity was found to be strongly associated with thrombosis. With increasing aPL titers (eg, from the 95th to the 99th percentile), a trend of an increased risk for thrombosis was obtained.
With the manufacturers' cutoff, the sensitivity and specificity varied, respectively, from 7.1% to 9.9% and 94.7% to 96.3% for Moreover, the in-house cutoff is calculated by the 99th percentile by 82.4% of the laboratories, as advised, although not always using at least 120 normal controls (53.7%); 61.5% of the laboratories check for outliers by various methods, and 38.2% of those using the manufacturer's cutoff check the cutoffs before transferring them.
| DISCUSSION
The goal of this study was to calculate and compare cutoff values for aCL and aβ2GPI antibodies analyzed on 4 different platforms and to define the optimal method of calculation by analyzing the diagnostic performance in a case-control design. Previous studies defining optimal aPL cutoffs focused on the optimal separation of cases and controls. 9, 14 However, this approach has inherent weaknesses. 15, 16 Instead, we propose a different approach that takes advantage of the Youden index to select the optimal cutoff value.
The aPL results from the normal controls were not normally tiles of a population using nonparametric statistics. 11 In fact, the minimum sample size for a reliable estimation of the 99th percentile is at least 300. 17 Currently, only medium-or high-titer antibodies are considered clinically relevant. 18, 19 This study confirms an increased risk for thrombosis with increasing aPL titers (eg, from the 95th to the 99th percentile), although the application of the 99th percentile may be inappropriate for clinical use due to low sensitivity. For example, for HemosIL AcuStar aβ2GPI IgG, the titer of 136.2 U/mL calculated as the 99th percentile of 120 normal controls is associated with a disappointingly low sensitivity, dropping to <20%.
When selecting subjects for a reference range study, we assume that the reference values represent a "homogeneous" collection of observations. The question remains how to treat those subjects that are apparently aberrant. Many papers evaluating cutoff values for aPL simply assume the absence of outliers. 20, 21 This is based on the assumption that samples from normal donors are negative for all aPL. However, given the high titer of aPL, the subjects classified as outliers in this study were regarded as true biological outliers. Of note, the presence of aPL in a patient can precede the occurrence of the typical clinical manifestations.
Our findings suggest the need for outlier removal as a necessary step before cutoff calculation, as the reference study is prone to biological outliers on top of analytical outliers. The CLSI guideline 11 supports the use of the Reed method, in which the suspected outlier is rejected if the distance between the value and its closest neighbor is more than one third of the range of all values. However, this test can be used only when 1 outlier is suspected. 22 Tukey's box method involves the labeling of extreme values by using only the middle 50% of the sample, thus reducing the possible masking effect of multiple outliers at 1 site of the distribution. However, Tukey's box method requires transformation to yield a parametric distribution. Alternatively, a block procedure, such as the TM test, 13, 23 is suggested. No further details are given in the CLSI document about the use of this method that is also not available in conventional statistical software programs.
The existence and support of multiple outlier detection methods complicates which method should be used, given the impact on the resulting cutoff value and hence the classification of patients.
Some limitations of our study should be recognized. First, the optimal minimum number of 300 normal donors was not reached.
This may explain the considerable differences in cutoff estimations depending on the method used. Second, we did not include obstetric APS patients in this study. Some of those patients may have lower, yet persistent, aPL levels and could be more adversely affected by cutoff calculations. A small number of reports [24] [25] [26] associate low titers of aPL with an increased risk of obstetric complications, though further confirmation in additional studies is necessary.
Considering the diagnostic importance of the 99th percentile in the prediction of APS-related thrombosis, we emphasize the need for standardized criteria concerning the statistical analysis to define the 99th percentile. Based on our results, we recommend the use of a nonparametric procedure based on at least 300 samples from normal donors. To identify outlier data, we recommend the use of the Reed method given its simplicity. Moreover, applying this outlier exclusion method results in a high Youden index.
The sample size requirement causes a problem concerning the feasibility of local laboratories to establish cutoff values.
Verification of the manufacturer's cutoff using a small number may be an alternative when local cutoff calculation is not feasible. 6 However, this would assume that manufacturers' cutoffs are established by appropriate statistical models using a sufficiently large donor population. In our experience, this is not always the case.
A better alternative to establish cutoff values is a multicenter approach. Previously, it was demonstrated that a multicenter approach can determine the cutoff values with a higher accuracy by increasing the number of healthy blood bank donors. 21 An interlaboratory cutoff value established by users of an identical automated system, applying the same sample type with comparable demographic characteristics of patients, was evaluated as a valuable alternative by 90% of the participants of the questionnaire. Joint efforts of independent organizations, such as national or international external quality control organizations or standardization committees such as the SSC-aPL, can render this approach more cost-effective and achievable, having the advantage of pooling results of higher numbers of normal donors, and applying a good design.
Uniformity in the calculation of cutoff values will lead to an improved and more standardized interpretation of assays and benefit the complex diagnosis of APS.
